Monica Latia, Andreea Bena, Luciana Moisa-Luca, Ștefania Bunceanu, Dana Stoian
{"title":"Shear wave elastography for thyroid nodule evaluation in patients with chronic autoimmune thyroiditis.","authors":"Monica Latia, Andreea Bena, Luciana Moisa-Luca, Ștefania Bunceanu, Dana Stoian","doi":"10.1007/s12020-025-04159-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Shear wave elastography (SWE) is a valuable tool in discerning the malignancy risk of thyroid nodules. This study investigates whether 2D-SWE can reliably differentiate malignant thyroid nodules in patients with chronic autoimmune thyroiditis (CAT), despite the challenges posed by fibrosis, which can increase tissue stiffness and complicate diagnosis.</p><p><strong>Methods: </strong>This retrospective observational study evaluated 130 thyroid nodules (91 benign, 39 malignant) in patients with underlying CAT using conventional ultrasound (B-mode) and 2D-SWE with SuperSonic Mach30 equipment (Supersonic Imagine, Aix-en-Provence, France). Pathology reports served as the reference standard.</p><p><strong>Results: </strong>Out of the 130 nodules, 30% were malignant, and 70% were benign. 2D-SWE proved to be an excellent distinguisher between benign and malignant nodules. Malignant nodules had significantly higher elasticity indices compared to benign nodules (mean elasticity index: 47.2 kPa vs. 18.1 kPa, p < 0.0001; maximum elasticity index: 75 kPa vs. 26.2 kPa, p < 0.0001). The mean elasticity index was the most reliable elastographic parameter (AUC 0.907, sensitivity 87.2% [95% CI: 77.3-94.0%], specificity 84.6% [95% CI: 75.4-91.5%], and NPV 93.9% for a cut-off value of 30.5 kPa).</p><p><strong>Conclusion: </strong>Our results confirm that 2D-SWE can accurately diagnose malignant thyroid nodules in cases with CAT (p < 0.0001), supporting its use as a complementary tool to conventional ultrasound.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04159-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Shear wave elastography (SWE) is a valuable tool in discerning the malignancy risk of thyroid nodules. This study investigates whether 2D-SWE can reliably differentiate malignant thyroid nodules in patients with chronic autoimmune thyroiditis (CAT), despite the challenges posed by fibrosis, which can increase tissue stiffness and complicate diagnosis.
Methods: This retrospective observational study evaluated 130 thyroid nodules (91 benign, 39 malignant) in patients with underlying CAT using conventional ultrasound (B-mode) and 2D-SWE with SuperSonic Mach30 equipment (Supersonic Imagine, Aix-en-Provence, France). Pathology reports served as the reference standard.
Results: Out of the 130 nodules, 30% were malignant, and 70% were benign. 2D-SWE proved to be an excellent distinguisher between benign and malignant nodules. Malignant nodules had significantly higher elasticity indices compared to benign nodules (mean elasticity index: 47.2 kPa vs. 18.1 kPa, p < 0.0001; maximum elasticity index: 75 kPa vs. 26.2 kPa, p < 0.0001). The mean elasticity index was the most reliable elastographic parameter (AUC 0.907, sensitivity 87.2% [95% CI: 77.3-94.0%], specificity 84.6% [95% CI: 75.4-91.5%], and NPV 93.9% for a cut-off value of 30.5 kPa).
Conclusion: Our results confirm that 2D-SWE can accurately diagnose malignant thyroid nodules in cases with CAT (p < 0.0001), supporting its use as a complementary tool to conventional ultrasound.
期刊介绍:
Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.
Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.
Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.